Getinge

Report Publication Announcement • Jan 17, 2013

PRESS RELEASE 2013-01-17

Getinge announces date of 2012 Q4 report and conference call

GETINGE will issue its Q4 report for 2012 on Friday 25th of January 2013 at 12:00 CET, followed by a conference call at 14:00 CET, hosted by Johan Malmquist, CEO, and Ulf Grunander, CFO.

To participate in the conference, please dial: Swedish dial in number: +46 8 5352 6408 UK dial in number: +44 20 3364 5381 US dial in number: +1 646 254 3366 Participant passcode: 7506740

Agenda 13:45 Call in to the conference 14:00 Review of the Q4 report 14:20 Q&A 15:00 Close of the conference

A recorded version of the conference can be accessed for 5 working days on the following number: Sweden: +46 8 5051 3897 UK: +44 20 3427 0598 US: +1 347 366 9565 Code: 7506740

During the telephone conference a presentation will be held. To access the presentation, please use this link: http://www.livemeeting.com/cc/premconfeurope/join?id=7506740&role=attend&pw=pw9390

Alternatively enter the VisionCast site and log into your meeting using the Meeting ID and Password below: VisionCast: http://www.euvisioncast.com Your Name: (Enter your name) Web Meeting ID: 7506740 Web Meeting Password: pw9390

For more information, please contact: Kornelia Rasmussen Group Communications Phone: +46 (0)10 335 5810 E-mail: kornelia.rasmussen@getinge.com

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.